In primary aldosteronism, must spironolactone be stopped before adrenal venous sampling?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Spironolactone Withdrawal Before Adrenal Venous Sampling in Primary Aldosteronism

Yes, spironolactone must be stopped before adrenal venous sampling (AVS), with current guidelines recommending withdrawal for at least 4–6 weeks prior to the procedure.

Withdrawal Requirements

Spironolactone should be discontinued for a minimum of 6 weeks before AVS, while eplerenone requires at least 4 weeks of withdrawal. 1 The most recent Endocrine Society guideline (2025) and American College of Cardiology consensus both mandate that all mineralocorticoid receptor antagonists (MRAs) be withdrawn for ≥4 weeks prior to AVS. 1

Physiologic Rationale for Withdrawal

  • MRAs stimulate aldosterone secretion from the contralateral (normal) adrenal gland through feedback mechanisms, which artificially lowers the lateralization index and can produce false-negative AVS results. 1 This interference would inappropriately exclude patients from potentially curative surgery by masking true unilateral disease.

  • The drug-induced bilateral aldosterone production obscures the distinction between the hyperfunctioning and normal adrenal gland, making lateralization assessment unreliable. 1

Alternative Blood Pressure Management During Withdrawal

During the MRA withdrawal period, blood pressure must be controlled with antihypertensive agents that do not affect the renin-angiotensin-aldosterone system. 1 Suitable options include:

  • Alpha-blockers (doxazosin, prazosin, terazosin) 1
  • Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) 1
  • Dihydropyridine calcium channel blockers (nifedipine) 1
  • Direct vasodilators (hydralazine) 1

ACE inhibitors and angiotensin receptor blockers must also be discontinued during this period, as they interfere with renin-angiotensin-aldosterone system measurements. 1

Pre-Procedure Biochemical Preparation

Serum potassium must be corrected to within the laboratory reference range before AVS. 1 Hypokalemia suppresses aldosterone secretion and can cause false-negative lateralization results, potentially misclassifying unilateral disease as bilateral. 1

Plasma renin activity (PRA) should be measured immediately before AVS to confirm adequate renin suppression (PRA <0.5 ng/mL/hr or direct renin concentration <25 mIU/L). 1 This confirms that the withdrawal period has been sufficient for reliable interpretation.

Patients should maintain unrestricted dietary sodium intake during the preparation period. 1 Sodium restriction would provoke compensatory aldosterone release from both adrenal glands, confounding lateralization assessment.

Shortened Withdrawal Protocol: Evidence and Caveats

While standard guidelines recommend 4–6 weeks of MRA withdrawal, one single-center study demonstrated that a 2-week withdrawal protocol achieved renin suppression in 94% of patients (30/32), with 100% diagnostic success rates. 2 However, this represents lower-quality evidence from a small case series and has not been incorporated into major guidelines.

The safest approach remains adherence to the guideline-recommended 4–6 week withdrawal period, particularly given that the physiologic rationale for longer withdrawal is well-established. 1 The 2-week protocol should only be considered in exceptional circumstances where patients cannot safely tolerate longer withdrawal due to severe hypertension or hypokalemia, and only if renin suppression is confirmed immediately before AVS. 2

Clinical Context

The French consensus (2016) notes that spironolactone administered during the weeks preceding surgery controls hypertension and hypokalemia and may prevent postoperative hypoaldosteronism, 3 but this refers to the post-AVS period after lateralization has been confirmed and surgery is planned—not to continuation during the diagnostic AVS procedure itself.

Failure to withdraw MRAs adequately before AVS represents a critical pitfall that can result in missed surgical candidates and unnecessary lifelong medical therapy for patients with curable unilateral disease.

References

1
Guideline

Pre‑Adrenal Venous Sampling Management of Mineralocorticoid Receptor Antagonists

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Which antihypertensive medications are safe to use during adrenal vein sampling?
In a 34-year-old patient on Adderall presenting with hypertension (blood pressure 154/100 mm Hg), how should the hypertension be managed?
After initiating Kerentia (finerenone), which laboratory tests need to be checked and at what frequency?
For a 24‑hour urine aldosterone test, should the urine be collected in a plastic container and kept refrigerated, or is room‑temperature storage acceptable?
What is the appropriate evaluation and management for a 54-year-old male with primary hyperaldosteronism presenting with heat‑induced palpitations and generalized weakness?
What alternative medications can be used instead of ivabradine to manage tachycardia?
Compare and contrast Disseminated Intravascular Coagulation, Sepsis‑Induced Coagulopathy, and Trauma‑Induced Coagulopathy, describing each condition’s pathophysiological drivers, the recommended diagnostic scoring systems (e.g., International Society on Thrombosis and Haemostasis criteria), and evidence‑based thresholds for anticoagulation versus blood product administration.
Which fabrics have been shown to contain endocrine‑disrupting chemicals that can affect hormone function?
What are the clinical phases of acute hepatitis B infection?
Has rayon been demonstrated to be an endocrine-disrupting chemical?
What are the psychological causes of hyper‑vigilance in individuals who feel they notice everything, and how should it be evaluated and treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.